Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1966 2
1967 1
1968 5
1969 4
1970 8
1971 7
1972 7
1973 6
1974 8
1975 17
1976 17
1977 18
1978 9
1979 18
1980 26
1981 15
1982 21
1983 11
1984 16
1985 16
1986 12
1987 11
1988 14
1989 11
1990 12
1991 15
1992 13
1993 14
1994 15
1995 20
1996 14
1997 18
1998 26
1999 21
2000 33
2001 30
2002 38
2003 27
2004 44
2005 49
2006 50
2007 54
2008 45
2009 54
2010 76
2011 60
2012 69
2013 56
2014 58
2015 79
2016 75
2017 63
2018 51
2019 59
2020 68
2021 74
2022 81
2023 64
2024 35

Text availability

Article attribute

Article type

Publication date

Search Results

1,676 results

Results by year

Filters applied: . Clear all
The following term was ignored: %
The following term was not found in PubMed: 20Salonen
Page 1
Targeting MET Dysregulation in Cancer.
Recondo G, Che J, Jänne PA, Awad MM. Recondo G, et al. Cancer Discov. 2020 Jul;10(7):922-934. doi: 10.1158/2159-8290.CD-19-1446. Epub 2020 Jun 12. Cancer Discov. 2020. PMID: 32532746 Free PMC article. Review.
Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers.
Kobayashi Y, Chhoeu C, Li J, Price KS, Kiedrowski LA, Hutchins JL, Hardin AI, Wei Z, Hong F, Bahcall M, Gokhale PC, Jänne PA. Kobayashi Y, et al. Nature. 2022 Mar;603(7900):335-342. doi: 10.1038/s41586-022-04451-4. Epub 2022 Mar 2. Nature. 2022. PMID: 35236983
An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer.
To C, Beyett TS, Jang J, Feng WW, Bahcall M, Haikala HM, Shin BH, Heppner DE, Rana JK, Leeper BA, Soroko KM, Poitras MJ, Gokhale PC, Kobayashi Y, Wahid K, Kurppa KJ, Gero TW, Cameron MD, Ogino A, Mushajiang M, Xu C, Zhang Y, Scott DA, Eck MJ, Gray NS, Jänne PA. To C, et al. Nat Cancer. 2022 Apr;3(4):402-417. doi: 10.1038/s43018-022-00351-8. Epub 2022 Apr 14. Nat Cancer. 2022. PMID: 35422503 Free PMC article.
Resistance in trans-ition.
Vokes NI, Jänne PA. Vokes NI, et al. J Thorac Oncol. 2017 Nov;12(11):1608-1610. doi: 10.1016/j.jtho.2017.09.1953. J Thorac Oncol. 2017. PMID: 29074207 Free article. No abstract available.
Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor.
To C, Jang J, Chen T, Park E, Mushajiang M, De Clercq DJH, Xu M, Wang S, Cameron MD, Heppner DE, Shin BH, Gero TW, Yang A, Dahlberg SE, Wong KK, Eck MJ, Gray NS, Jänne PA. To C, et al. Cancer Discov. 2019 Jul;9(7):926-943. doi: 10.1158/2159-8290.CD-18-0903. Epub 2019 May 15. Cancer Discov. 2019. PMID: 31092401 Free PMC article.
[Fungal infections].
Köhler P, Cornely OA, Vehreschild JJ. Köhler P, et al. Internist (Berl). 2019 Jul;60(7):684-689. doi: 10.1007/s00108-019-0618-3. Internist (Berl). 2019. PMID: 31119309 Review. German.
1,676 results